Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis

作者：Saigusa Ryosuke; Asano Yoshihide^*; Nakamura Kouki; Miura Shunsuke; Ichimura Yohei; Takahashi Takehiro; Toyama Tetsuo; Taniguchi Takashi; Noda Shinji; Aozasa Naohiko; Akamata Kaname; Sumida Hayakazu; Miyazaki Miki; Tamaki Zenshiro; Yanaba Koichi; Kuwano Yoshihiro; Sato Shinichi

来源：Journal of Dermatology, 2015, 42(5): 524-527.

DOI：10.1111/1346-8138.12827

• anti-RNA polymerase III antibody
• Japanese
• malignancy
• synchronous onset
• systemic sclerosis

Patients with systemic sclerosis (SSc) have an increased risk of malignancy compared with the general population. Recently, SSc patients with anti-RNA polymerase III antibody have been reported to have an increased risk of malignancy as compared with those with other disease-specific autoantibodies in US, European and Australian populations. Therefore, we studied the relationship between disease-specific autoantibodies and malignancy in 261 Japanese SSc patients. The prevalence of malignancy was significantly higher in patients with anti-RNA polymerase III antibody (7/22, 31.8%) than in those with anti-topoisomerase I antibody (2/82, 2.4%) and in those with anticentromere antibody (8/137, 5.8%). Importantly, among seven patients with anti-RNA polymerase III antibody and malignancy, three patients (42.9%) developed malignancy from 6months before to 12months after SSc onset. Thus, malignancy complication in Japanese SSc patients with anti-RNA polymerase III antibody is as high as that in other races, suggesting that SSc patients with anti-RNA polymerase III antibody share the same pathological process among different ethnic groups.

• 出版日期2015-5